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1062Objective: Cost-effectiveness of heart surgery for elderly patients is still poorly defined. We evaluated outcome,
quality of life (QoL), cost, and cost-effectiveness of octogenarians undergoing cardiac surgery.
Methods: One thousand six hundred forty octogenarians undergoing various cardiac surgical procedures were
prospectively studied between January 1998 and January 2009 and compared with similar patients aged 70 to 79
years. Several questionnaires were used to assess QoL. Six hundred age- and sex-matched healthy octogenarians
and three hundred forty patients older than 80 years with medically treated valvular or coronary artery disease
were healthy and unoperated control groups, respectively. In-hospital costs were obtained from the hospital’s
financial accounting department and cost-effectiveness was estimated and expressed as cost/QoL-adjusted
life year (QALY) and cost-effectiveness ratio.
Results: Significant improvements occurred in elderly patients in Role Physical (P< .001), Bodily Pain
(P<.001), General Health (P ¼ .004), Social Functioning (P<.001), and Role Emotional (P<.001), whereas
Physical Functioning, Vitality, and Mental Health did not change (difference not signficant). Total direct costs
were $5293 higher in the octogenarian group. Cost-effectiveness was $1391/QALY for elderly surgical patients,
$516/QALY for younger cardiac surgical patients (P<.001 vs elderly), $897/QALY for untreated control group,
and $641/QALY for healthy control group (P<.001 vs elderly surgical patients). The cost-effectiveness ratio for
octogenarians was $94,426.
Conclusions: Our findings confirm that cardiac surgery in elderly patients remains controversial from a cost–
effectiveness standpoint, making econometric analysis an important component for any future evaluation of
novel cardiovascular therapies. Our findings need to be confirmed by additional multicenter studies. (J Thorac
Cardiovasc Surg 2011;142:1062-73)Population aging is a shift in the distribution of a country’s
population toward greater ages in the developed countries.1
The sources of population aging lie in 2 possibly related de-
mographic phenomena: rising life expectancy, largely as
a result of the improvements in medical care being offered
to the elderly population, and declining fertility, with the
latter being the dominant contributor to population aging
in the world today.2
It has been estimated that the world population will in-
clude more than 400 million persons at least 80 years old
by the year 2050.1 This phenomenon is more noticeable
in Italy, which has one of the oldest populations on the
planet and which will include more than 7.2 million persons
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Because more than 40% of elderly persons have symp-
tomatic cardiac disease,3 an increasing number of these
patients may become candidates for cardiac surgery. More-
over, continuous advances in operative technique, myocar-
dial protection, and perioperative care have led to
a worldwide increase in cardiac surgery procedures for
this age group.4 Nonetheless, controversy exists as to
whether the considerable proportion of health care re-
sources spent on the growing minority of elderly patients
represents a cost-effective approach. To answer this ques-
tion, we evaluated results, quality of life, costs, and resource
use associated with cardiac surgery in octogenarians.MATERIALS AND METHODS
Patients
One thousand six hundred forty consecutive patients at least 80 years
old undergoing cardiac surgery at 3 Italian institutions (Careggi Hospital,
Florence, Civic Hospital, Brescia, and S. Maria Misericordia Hospital,
Udine) between January 1998 and January 2009 were enrolled in the study.
One thousand two hundred thirty consecutive patients aged 70 to 79 years
undergoing cardiac operations during the same period were used as a com-
parison group for early and late outcomes, costs, and quality of life to testgery c November 2011
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good and cost-effective as in septuagenarians. No exclusion or inclusion
criteria were applied.
Costs and quality of life for patients at least 80 years old undergoing
heart operations were further compared with those of 340 control octoge-
narians with unoperated heart disease (UC group). These were patients
with valvular or coronary artery disease who were comparable to the study
group in terms of clinical characteristics, severity of illness, and disability
and who had the indication for the intervention given by a cardiac surgeon
but were medically treated rather than undergoing surgery. Most of these
patients refused the intervention (85%) or had a ‘‘technical’’ contraindica-
tion to surgery (15%, eg, porcelain aorta). The same analysis and cost as-
sessment were applied and compared with results of actual surgical
candidates. For this reason, there were no missing calculations in this
data analysis. To explore whether the cost-effectiveness of cardiac surgery
in elderly patients compares favorably with the social cost of the general
elderly population, costs and quality of life of octogenarians undergoing
heart operations were compared with those of 600 age-matched healthy
(absence of neoplasm, chronic disease, cardiac disease) control subjects
(HC group), and costs and quality of life of septuagenarians undergoing
heart operations were similarly compared with those of an age-matched
HC group (n¼ 486). Subjects in the HC groups were enrolled by 3 general
practitioners linked to our clinical practice during the same period as the
study. No formal exclusion criteria were applied.
Patients were enrolled and followed up by S.G., who was staff surgeon
in these 3 institutions during the study period. Median follow-up was 69.8
months (interquartile range, 30.8–107.9 months).
In all cases, extubation was rigorously controlled per protocol. Age did
not bias the protocol, and the decision to extubate was made independently
of the surgeon and in a committed ‘‘early extubation’’ program.
Furthermore, all transfusions were given only per protocol, not by bedside
judgment.
The age of the patient was never a factor in the use of blood products.
All patients with hemoglobin below 10 g/dL underwent blood transfusion,
and no difference was detected between octogenarians and septuagenar-
ians with regard to the number of patients undergoing transfusion, be-
cause most patients who were anemic in the preoperative period had
values between 10 and 13 g/dL. In accordance with the World Medical
Association guidelines concerning ethical principles for medical research
involving human subjects, the study was approved by the institutional
ethics boards, and surgical candidates gave informed consent. Potential
candidates who declined surgery and other control subjects gave informed
consent to be included in the study. We had full access to the data and take
responsibility for its integrity. All of us have read and agree to the article
as written.The Journal of Thoracic and CarQuality of Life Assessment
Patients undergoing surgery were administered quality of life question-
naires preoperatively and at any follow-up appointments, along with clin-
ical examination and echocardiographic control. Among survivors,
seventy-six patients (4.3%) were not able to participate in the follow-up
questionnaires. Reasons for nonparticipation included Alzheimer disease
(n ¼ 10), other neurologic problems (n ¼ 11), refusal (n ¼ 18), language
barriers (n ¼ 7), data entry problems (n ¼ 3), terminal cancer (n ¼ 12),
and others (n ¼ 15).
Patients in the UC group were routinely administered quality of life
questionnaires after admission and then followed up on a regular basis
by cardiologists and cardiac surgeons, undergoing quality of life assess-
ment at a median of 9 months (range, 4–13 months) from first admission
to the surgery waiting list. Subjects in the HC group were followed up
by the general practitioners who enrolled them in the study. For these sub-
jects, quality of life questionnaires were administered at randomly chosen
times at general practitioner clinics or by phone. All interviews were car-
ried out by 2 surgeons (G.M., F.L.), both of whom were blinded to the
aims of the study. The median time spent on interview was 28 minutes
(interquartile range, 20–37 minutes).
Quality of life was measured with the Medical Outcomes Short Form
36-Item Health Survey (SF-36),5 which consists of 36 questions grouped
into the following 8 multi-item domains (Appendix Table 1).: Physical
Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role Emotional, and Mental Health. Furthermore, SF-36
also assesses 2 major health concepts, physical and mental, with 2 compos-
ite scores, the physical composite score (PCS) and the mental composite
score (MCS). The physical scales (Physical Functioning, Role Physical,
Bodily Pain, and General Health) make up the PCS, and the remaining 4
scales (Mental Health, Role Emotional, Vitality, and Social Functioning)
make up the MCS. Reliability by the test–retest6 between baseline and at
follow-up was good, with interclass correlation coefficients ranging be-
tween 0.73 and 0.86. Internal consistency6 was good for the 8 scales,
with Cronbach coefficients ranging between 0.85 and 0.95.
The Seattle Angina Questionnaire was only applied to those patients
with coronary artery disease necessitating isolated coronary artery bypass
grafting (CABG).7 It represents a reliable and validated instrument that
measures 5 clinical dimensions of health in patients with coronary artery
disease (physical limitation, anginal stability, anginal frequency, treatment
satisfaction, and disease perception).
Zung’s Self-Rating Depression Scale (SDS)8 was used to assess depres-
sion. The questionnaire consists of 20 questions,10 symptomatically posi-
tive and 10 symptomatically negative. Results were expressed as SDS raw
score (sum of points for all 20 questions), SDS average score, and SDS
index.
The Italian version of the Spielberger State-Trait Anxiety Inventory
form X1 was used to measure state anxiety (how one feels at a particular
moment), whereas form X2 was used to assess trait anxiety (how one usu-
ally feels).9 The scores range from 20 (very low anxiety) to 80 (very high
anxiety).
Costs
In-hospital costs were obtained from the hospitals’ financial accounting
departments. All billed items and their associated costs were assigned to 1
of the following 15 categories: preoperative (all costs before surgery),
anesthesia (costs of anesthetics, equipment, and disposables used by anes-
thesiologists), operative (costs related to the use of the operating rooms and
all surgical equipment and disposables used by surgeons), perfusion (costs
of cardiopulmonary bypass equipment, cardioplegia, and disposables used
by perfusionists), intensive care unit (ICU, costs of nursing, equipment,
and room in the cardiovascular ICU), postoperative room (costs related
to nursing, equipment, and room in the step-down unit), respiratory therapy
(costs related to respiratory equipment, treatments, and therapist time), lab-
oratory (costs of blood tests), blood bank (costs related to blood typing anddiovascular Surgery c Volume 142, Number 5 1063
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diograms, and other noninvasive vascular studies), radiology (costs of ra-
diographs, computed tomographic scans, and magnetic resonance scans),
pharmacy (costs of drugs and dispensing), therapies (costs of physical,
occupational, and speech therapy), supplies, and other costs.
Postoperative costs were assigned to the following categories: physi-
cian visits, echocardiograms, anticoagulation therapy, rehospitalization,
reoperation, complications, pharmacy, specialties, home care facilities,
and other. We first calculated costs in the entire cardiac surgical popula-
tion. Then operations were broken down into 6 categories: CABG, off-
pump CABG, aortic valve replacement, mitral valve replacement, mitral
valve repair, aortic surgery (including surgery of the ascending aorta or
aortic arch, with or without a prosthetic valve), and associated CABG
and valve surgery.
Costs in HC and UC groups were divided into the following categories:
home and skilled nursing facilities, general medicine, pharmacy, hospital-
ization, specialties, therapies, diagnostics, and other. These costs were ob-
tained directly from institutions’ cost-accounting systems or from Health
Ministry rates for services.
Prices were originally calculated in euros, converted to 2009 value with
yearly inflation factors10 obtained from the consumer price index, and then
changed to US dollars (V1 ¼ $1.4406 US, currency rate as of January 1,
2010).Cost-effectiveness
To calculate cost-effectiveness, the sum of lifetime costs was divided by
the total quality-adjusted life years (QALYs)11 gained. The result was then
divided by the number of patients.
The lifetime total costs in the operative groups were obtained by sum-
ming (1) in-hospital costs, (2) postoperative costs, and (3) for subjects
who are currently alive, estimated lifetime costs.
Estimated survival after cardiac surgery was determined from the
observed data from our follow-up system and completion of the currently
censored lifetimes with a Gompertz regression model derived from the
observed patient data.11 The simulation was repeated 1000 times, and the
mean was used in the final calculation.11
Estimated lifetime costs were assigned to the following categories: phy-
sician visits, echocardiograms, anticoagulation therapy, re-hospitalization,
re-operation, complications, pharmacy, specialties, home care facilities,
and other. Data reflect resource acquisition costs, allocation of institutional
cost, and indirect institutional costs derived from data obtained from Re-
gional Health Care Administration Offices (Friuli Venezia Giulia, Toscana,
Lombardia) or obtained from the service rates from the Italian Ministry of
Health. To project the cost during these simulated future life years, physi-
cian visits and echocardiograms were assumed to occur annually.11,12
Hospitalization, rehospitalization, and reoperation were obtained by
applying the hazard function to observed data. Complications not related
to time were assumed to occur at the same constant rates during the
observed patient-years.
QALYs were calculated on the basis of raw PCS and MCS. For both
scores, each year in perfect health was assigned the value from 1 (maxi-
mum score 100) down to the value of 0.0 (minimum score 0), and values
were added. For future simulated life years, PCS and MCS scores were lin-
early interpolated between the latest available raw scores and 0 (assumed
for the end of life).
The life years of patients with unoperated heart disease or of healthy oc-
togenarians were estimated from data obtained from the Italian National In-
stitute of Statistics and from the Italian Superior Institute of Health
concerning the natural history of unoperated surgical heart diseases, and
a survival curve was built for each group. An average curve was then com-
puted, weighted by sample size, and the area under this curve was the mean
survival time. Each patient was randomly assigned a lifetime by sampling
the survival time on the survival curves according to the probability of
survival.111064 The Journal of Thoracic and Cardiovascular SurEstimated lifetime costs were assigned to same subcategories used for
operative patients. To project the cost during these simulated future life
years, rates of physician visits, echocardiograms, hospitalization, and so
on were obtained by the hazard function from data obtained from the Italian
Superior Institute of Health and the Italian Ministry of Health.
QALYswere calculated as described. Similarly, for future simulated life
years, PCS and MCS scores were linearly interpolated between the latest
available raw scores and 0 (assumed for the end of life).
To allow a comparison with published reports, we also calculated a cost-
effectiveness ratio (CER), as suggested byWu and coworkers.11 Briefly, the
CER was the difference between the lifetime cost of operative patients and
the lifetime cost of UC group patients (set at 0) divided by the difference in
quality of life experienced by operative and UC groups. The QUALYs were
estimated by mapping quality of life scores versus New York Heart Asso-
ciation (NYHA) functional class. Life years spent in NYHA functional
classes I, II, III, and IV were estimated to be equivalent to 0.85, 0.71,
0.57, and 0.43 QALYs, respectively. On the basis of generally accepted
thresholds, a treatment with a CER less than $20,000 is considered highly
cost-effective, a treatment with a CER between $20,000 and $100,000 is
acceptable but gradually less cost-effective, and a treatment with a CER
more than $100,000 is not cost-effective.11Statistical Analysis
Variables were tested for their normal (Gaussian) distribution with the
Kolmogorov–Smirnov test. Continuous data were expressed as mean 
SD, nonparametric data were presented as median and interquartile range,
and frequencies were expressed as proportions. Categoric variables were
compared with c2 or Fisher’s Exact test. We used Student t tests (unpaired)
to compare continuous variables, except when data were skewed, in which
case the Mann–Whitney and the Wilcoxon tests were used for paired and
unpaired comparisons, respectively, whereas the Kruskal–Wallis and the
Friedman tests were used for matched and nonmatched multiple compari-
sons. The Dunn nonparametric post hoc test was then used to compare each
pair of variables. No type I error adjustment was made for multiple testing.
Freedoms from death, cardiac events, and rehospitalization were esti-
mated by use of the Kaplan–Meier method. Log-rank was used to detect
differences between curves.
A multivariable Cox model was used to select independent predictors of
death after the assessment of the proportional hazard assumption. The ln
(ln) survivor curves were assessed for categoric variables and quartiles
of continuous variables. When curves were not roughly parallel, further
evaluation was performed by including an interaction term of the covariate
with time, which was evaluated for significance (P<.05) and for whether
inclusion resulted in a change of at least 20% in the hazard ratio for the
main effect. When these criteria were used, no significant departure from
the proportional hazard assumption was found. Models were validated
with bootstrapping technique (1000 iterations).
The Cox model was fitted to compute the hazard ratio for death after
adjustment for potential confounders (hypertension, smoking, diabetes,
obesity, hypercholesterolemia, chronic renal disease, chronic obstructive
pulmonary disease, cerebrovascular disease, NYHA class, EuroSCORE,
pulmonary hypertension, endocarditis, previous percutaneous transluminal
angioplasty, emergency-associated procedures, isolated CABG, multiple
valve procedures, aortic crossclamp time, and cardiopulmonary bypass
time). Backward stepwise selection was used, with a P value to remove
of .2.
Because of the skewness of the cost data, generalized linear regression
models13 were used that allow for nonnormal distributions. Our models
used a g error distribution, and the link function was logistic. Thus the
estimated regression coefficients are on the log scale, and their direction
and magnitude provide an indication of their effect: positive (negative)
values indicate increased (decreased) costs, with the cost multiplier being
approximately the exponent of the regression coefficient. With regard to
the cost modeling, however, because of the presence of cost values thatgery c November 2011
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other medical settings from which costs could be not be accurately ob-
tained), in some cases the censoring needed to be handled in the model-
ing. To examine the effect of censoring on in-hospital cost, we used the
method of Zhao and colleagues,14 which weights observations by the in-
verse probability of being censored and integrates across patients’ cost
histories to correct for censoring. This analysis revealed a negligible
bias resulting from censoring ($82), which also did not vary by age group
(operative octogenarian group vs operative septuagenarian group,
P ¼ .87).
SPSS version 12.0 (SPSS, Inc, an IBMCompany, Chicago, Ill) and Stats
Direct version 2.5.7 (StatsDirect, Sale, UK) software packages were used
for calculations.
RESULTS
Patient Characteristics
Clinical characteristics presented in Table 1 show signif-
icant differences between octogenarians and septuagenar-
ians with regard to gender (P<.001), anemia (P<.001),
chronic obstructive pulmonary disease (P¼ .005), cerebro-
vascular disease (P ¼ .002), and primitive neoplasm
(P ¼ .04), which occurred more in older patients. In con-
trast, octogenarians were less likely to have diabetes
(P ¼ .04) and hypercholesterolemia (P< .001). With re-
spect to operative procedures, the younger population had
more CABG (P ¼ .04) and on-pump CABG (P ¼ .03) pro-
cedures, whereas octogenarians received a larger number of
bioprosthetic valves (P ¼ .003).
Early and Late Outcomes
Outcome data are displayed in Table 2. Surgery in older
patients was associated with higher incidences of postoper-
ative atrial fibrillation (P ¼ .005) and agitation or disorien-
tation (P ¼ .004), a longer intubation time (P ¼ .004),
a greater need for blood transfusions (P<.001), and a longer
hospital stay (P < .001). Furthermore, octogenarians
showed a significantly higher in-hospital and 30-day mor-
tality (P<.001), with a lower percentage of patients dis-
charged to home (P < .001). Survival, freedom from
cardiac events, and freedom from rehospitalization at 1, 3,
5, and 8 years were significantly lower in octogenarians
(P<.001). At follow-up, NYHA functional class was sig-
nificantly higher in octogenarians (median, 2; interquartile
range, 2–3; vs median, 1; interquartile range, 1–2;
P ¼ .004). Predictors of death are shown in Table 3.
Quality of Life
Results of quality of life assessment are shown in Table
4. Quality of life of octogenarians undergoing heart oper-
ations was compared with age-matched UC and HC
groups. To make a comparison with the younger popula-
tion, quality of life of elderly patients (octogenarians)
was compared with that of septuagenarians, either opera-
tive or HC group. Younger patients showed a significant
improvement in quality of life across all SF-36 domains
(P<.001). Contrastingly, in the elderly group, significantThe Journal of Thoracic and Carimprovements occurred in Role Physical (P < .001),
Bodily Pain (P<.001), General Health (P ¼ .004), Social
Functioning (P< .001), and Role Emotional (P< .001),
whereas Physical Functioning, Vitality, and Mental Health
did not change (difference not significant). Relative to the
UC group, postoperative scores were higher in operative
group octogenenarians, exclusive of Physical Functioning,
Vitality, and Mental Health (difference not significant).
Furthermore, the elderly operative group had higher
scores for Bodily Pain (P ¼ .03), Social Functioning
(P ¼ .02), and Role Emotional (P ¼ .002) in comparison
with the HC group but showed lower scores in the Mental
Health domain (P ¼ .003). All scores were significantly
higher in younger patients than in elderly patients
(P< .001).
The entire cohort showed an improvement in Seattle An-
gina Questionnaire responses in all areas in the post-
operative period. Nonetheless, postoperative scores were
significantly higher in younger patients (P<.001).
Trait anxiety did not change in elderly patients (differ-
ence not significant), whereas state anxiety did improve
(P ¼ .03). Nonetheless, postoperative values of the elderly
operative group were comparablewith those of both UC and
HC groups. Contrastingly, both trait (P< .001) and state
(P ¼ .04) anxieties were reduced in younger patients after
surgery (P< .001 vs elderly). Finally, depression signifi-
cantly worsened after operation in octogenarians
(P < .001), whereas it improved in younger patients
(P ¼ .02; P<.001 vs elderly).
Costs and Cost–Benefit
Cost data by service area and multivariable predictors of
in-hospital costs are shown in Tables 5 and 6. Total direct
costs of octogenarians and septuagenarians undergoing
cardiac surgery were compared. Cost was higher in the
elderly cohort than in the younger cohort (þ$5293,
P< .001), with the largest increases in ICU (P ¼ .02),
respiratory therapy (P < .001), blood bank (P < .001),
and pharmacy (P ¼ .004).
Cost-effectiveness values of surgery for operative octo-
genarian and septuagenarian groups were compared with
the social cost of the general elderly population and with
the social and medical costs of octogenarians with cardiac
disease who did not undergo surgery. Cost-effectiveness
was $1391/QALY in the operative elderly group, $516/
QALY in younger cardiac surgical patients (P<.001 vs el-
derly), $897/QALY in UC group, and $641/QALY in HC
group (P<.001 vs. operated elderly). The CER for octoge-
narians was $94,426.
Costs and Cost–Benefit by Type of Intervention
Cost data by type of intervention are shown in Table 7.
Prices were consistently higher for octogenarians
(P< .001), with the largest differences in aortic surgerydiovascular Surgery c Volume 142, Number 5 1065
TABLE 1. Demographic and clinical characteristics
80 y (n ¼ 1640) 70–79 y (n ¼ 1230) P value
Age (y) <.001
Range 80–92 70–79
Mean  SD 83  2 72  3
Female (No.) 837 (51%) 382 (31.1%) <.001
Hypertension* (no.) 967 (58.9%) 627 (50.9%) .08
Diabetesy (no.) 393 (23.9%) 607 (49.3%) .004
Obesityz (no.) 49 (2.9%) 98 (7.9%) .054
Hypercholesterolemiax (no.) 311 (18.9%) 467 (37.9%) <.001
Smoking (no.) 393 (23.9%) 319 (25.9%) .6
New York Heart Association functional class
(median and interquartile range)
3 [2–4] 3 [2–4] >.9
Canadian Cardiovascular Society angina class
(median and interquartile range)
2 [1–3] 2 [1–3] .8
Anemiak (no.) 89 (5.4%) 9 (0.7%) <.001
Renal failure{ (no.) 279 (17.0%) 173 (14.1%) .08
Chronic obstructive pulmonary disease# (no.) 180 (10.9%) 57 (4.6%) .005
Peripheral vascular disease (no.) 200 (12.2%) 110 (8.9%) .068
Cerebrovascular disease (no.) 510 (31.1%) 221 (17.9%) .002
Myocardial infarction (no.) 352 (21.4%) 282 (22.9%) .09
Primitive neoplasm (no.) 93 (5.6%) 36 (2.9%) .04
Preoperative intra-aortic balloon pump (no.) 65 (3.9%) 51 (4.1%) .9
Congestive heart failure (no.) 459 (27.9%) 270 (21.9%) .054
Left main coronary disease (no.) 229 (13.9%) 209 (16.9%) .08
Previous percutaneous transluminal angioplasty (no.) 114 (9.3%) 87 (7.7%) .09
Left ventricular ejection fraction
(%, median and interquartile range)
46.5% [38.6%–49.9%] 47.7% [37.0%–48.6%] .79
Left ventricular ejection fraction<0.35 (no.) 286 (17.4%) 221 (17.9%) .9
Pulmonary hypertension** (no.) 78 (4.7%) 61 (4.9%) >.9
Endocarditis (no.) 5 (0.3%) 14 (1.1%) >.9
EuroSCORE (median and interquartile range)
Additive 9 [6–11] 10 [8–12] .73
Logistic 15 [10–16] 16 [11–18] .80
Status of surgery (no.) .81
Elective 673 (41.0%) 492 (40.0%)
Urgent 755 (46.0%) 591 (47.9%)
Emergency 212 (13.0%) 147 (11.1%)
Redo procedure (no.) 180 (10.9%) 144 (11.7%) .74
Surgical procedure data
Isolated CABG (no.) 567 (34.6%) 606 (49.3%) .04
On cardiopulmonary bypass (on-pump, no.) 238 (42.0%) 388 (64.5%) .03
Without cardiopulmonary bypass (off-pump, no.) 329 (58.0%) 213 (35.5%) .03
Conversion off-pump to on-pump (no.) 8 (2.4%) 6 (2.8%) .07
Grafts per patient (median and interquartile range) 2 [1–3] 2 [1–3] >.9
Arterial grafts per patient (median and interquartile range) 1 [0–1] 1 [0–1] >.9
Isolated valve (no.) 382 (23.3%) 119 (9.7%) <.001
CABG with valve (no.) 441 (26.9%) 284 (23.1%) .1
CABG with valve and other (no.) 130 (7.9%) 109 (8.9%) .18
Valve with other (no.) 113 (6.9%) 106 (8.6%) .07
Other (no.) 7 (0.4%) 6 (0.5%) >.9
Biologic prosthesis (no.) 1012 (94.1%) 490 (77.8%) .003
Mechanical prosthesis (no.) 64 (5.9%) 140 (22.2%) .003
Associated carotid endarterectomy (no.) 86 (5.2%) 50 (4.0%) .21
Other vascular operations (no.) 45 (2.7%) 23 (1.9%) .08
(Continued)
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TABLE 1. Continued
80 y (n ¼ 1640) 70–79 y (n ¼ 1230) P value
Cardiopulmonary bypass time
(min, median and interquartile range)
110 [98–144] 118 [100–157] .8
Aortic crossclamp time
(min, median and interquartile range)
73 [35–120] 75 [42–137] .8
CABG, Coronary artery bypass grafting. *Blood pressure greater than 140/90 mm Hg, history of high blood pressure, or need for antihypertensive medications. ySymptoms of
diabetes mellitus plus casual plasma glucose concentration of at least 200 mg/dL or fasting plasma glucose level of at least 126 mg/dL or 2-hour postprandial plasma glucose of at
least 200 mg/dL after 75-g glucose load. zBody mass index greater than 25.0 kg/m2. xSerum low-density lipoprotein cholesterol greater than 140 mg/dL or treatment with a statin.
kAccording to the World Health Organization criteria, anemia was defined as a hemoglobin concentration below 12 g/dL in women and below 13 g/dL in men. {Documented
serum creatinine greater than 2 mg/dL compared with normal 0.6 to 1.2 mg/dL. #Forced expiratory volume in 1 second less than 40%. **Mean pulmonary arterial pressure less
than 30 mm Hg.
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The subanalysis of cost data by service area showed that the
greatest increase in in-hospital costs for elderly patients
were for those referred to the ICU (þ$1221) and for respira-
tory therapy (þ$1009). Pharmacy costs were higher for
older patients in all types of interventions, whereas costs
of blood typing and transfusion were significantly higher
in more complex surgical procedures.
CER was significantly lower for septuagenarians inde-
pendent of the type of intervention (Figure 1, A). The
CER values for octogenarians were higher than $100,000
for aortic surgery and associated CABG and valve surgery
and above $20,000 in all cases (Figure 1, B).
DISCUSSION
Nationwide in Italy, cardiac surgery is being performed
more frequently in patients aged 80 years and older. None-
theless, controversy exists as to whether the considerably
high proportion of health-care resources expended on the
growing minority of elderly patients represents a cost-
effective approach in an attempt to maintain a meaningful
quality of life.15,16
Our results confirm that cardiac procedures can be
offered to octogenarians with acceptable morbidity and
mortality, significant improvement in clinical status, and
satisfactory long-term results, comparable with those re-
ported in the literature.17-19
Because our older patient group had lower prevalences of
diabetes and obesity (which may have been associated with
earlier death), one might have assumed better outcomes for
this group. In contrast, early mortality and complications
were significantly higher in elderly patients, even after
accounting for these risk factors.
Additionally, among older patients, an overall absolute
improvement was shown in SF-36 scores, although this
was lower than in younger patients. Specifically, improve-
ments were noted in the domains of Role Physical, Bodily
Pain, General Health, Social Functioning, and Role
Emotional, as well as in the MCS and PCS metascores.
There was little or no absolute improvement in Physical
Functioning, Vitality, and Mental Health. Compared with
the sex- and age-matched HC group, there were statisticallyThe Journal of Thoracic and Carsignificant improvements in Bodily Pain, Social Function-
ing, and Role Emotional domains, whereas Mental Health
score was lower. Finally, postoperative values for the SF-
36 domain were higher than in the UC group, although in
Physical Functioning, Vitality, and Mental Health, this
difference did not reach statistical significance.
Furthermore, those elderly patients who underwent
CABG were very satisfied with treatment and had stable
and infrequent anginal symptoms. Finally, elderly patients
showed a significant improvement in state anxiety, whereas
trait anxiety did not change, and depression significantly
worsened after operation. Thus our findings confirm an
improved postoperative quality of life for octogenarians
undergoing cardiac operations.16-21 Nonetheless, as the
expenses of health care are constantly increasing,
approaches to optimize costs in all departments of
medicine have a high priority. Thus every clinical
decision cannot set aside an accurate cost and cost–benefit
analysis. For this reason, the number of articles published
on cost–benefit analysis has increased enormously in
recent years.
In our experience, total costs were $5293 higher in the oc-
togenarian group, in accordance with reported data from
other investigators.4 This increase was attributable to higher
costs of ICU, respiratory therapy, blood bank, and phar-
macy. In addition, prolonged ICU stay, hospital stay, and in-
tubation time were, with sternal infection, independent
predictors of costs. Regardless, an age of at least 80 years
was the strongest predictor of in-hospital costs in our model.
A subanalysis of costs by intervention showed that costs
related to blood typing and transfusion were significantly
higher for octogenarians only in more complex procedures,
suggesting that adequate preoperative (eg, bone marrow
stimulation with erythropoietin, controlled preoperative
transfusion), intraoperative (ultra-filtration, prepriming of
the extracorporeal circuit with the patient’s own blood),
and postoperative (recombinant activated factor VII) man-
agement for anemia and bleeding are mandatory to improve
the outcome in elderly patients undergoing complex cardiac
surgery. Furthermore, our data suggest that respiratory com-
plications represent an important factor that significantly in-
creases costs of surgery in the elderly population. Detaileddiovascular Surgery c Volume 142, Number 5 1067
TABLE 2. Early and late outcomes
80 y (n ¼ 1640) 70–79 y (n ¼ 1230) P value
Significant bleeding, surgical reexploration* (no.) 146 (8.9%) 109 (8.8%) .9
Sternal infection (no.) 16 (0.9%) 17 (1.3%) .6.
Low output syndromey (no.) 148 (9.9%) 84 (6.9%) .06
Perioperative myocardial infarctionz (no.) 82 (5.0%) 62 (5.0%) >.9
Atrial fibrillationx (no.) 845 (51.5%) 385 (31.3%) .005
Permanent pacemaker (no.) 115 (7.0%) 62 (5.0%) .09
Postoperative intra-aortic balloon pump (no.) 17 (1.0%) 14 (1.1%) .8
Pneumoniak (no.) 98 (5.9%) 32 (2.6%) .06
Renal failure (no.)
Hemofiltration 39 (2.3%) 37 (3.0%) .25
Hemodialysis 50 (3.0%) 24 (1.9%)
Hepatic insufficiency (no.) 1 (0.1%) 2 (0.1%) .9
Neurologic dysfunction (no.)
Transient ischemic attack{ 36 (2.2%) 20 (1.6%) .1
Stroke# 123 (7.5%) 59 (4.8%) .18
Agitation, disorientation 118 (7.2%) 36 (2.9%) .004
Hemotransfusion (no.) 1594 (85.0%) 689 (56.9%) <.001
Red blood cells (IU, median and interquartile range) 5 [3–8] 2 [1–3] <.001
Platelets (IU, median and interquartile range) 1 [1–2] 1 [0–1] .01
Plasma (IU, median and interquartile range) 4 [3–5] 2 [1–3] <.001
Intensive care unit stay (d, median and interquartile range) 5 [3–8] 1 [1–3] <.001
Intubation time (h, median and interquartile range) 10 [6–18] 8 [4–15] .004
Intubation>5 d (no.) 131 (7.9%) 40 (3.2%) <.001
Reintubation (no.) 148 (9.1%) 40 (3.2%) <.001
Hospital stay (d, median and interquartile range) 15 [8–24] 10 [8–12] <.001
In-hospital death (no.) 121 (7.4%) 13 (1.0%) <.001
Discharged (no.) 1,519 (92.6%) 1,217 (99.0%)
Home (no.) 531 (35.1%) 741 (60.9%) <.001
Rehabilitation hospital (no.) 637 (41.8%) 408 (33.5%) .006
Other (no.) 351 (23.1%) 68 (5.6%) <.001
Early death** (no.) 135 (8.2%) 15 (1.2%) <.001
Freedom from late death (%)
1 y [patients at risk] 79%  6% [1318] 91%  4% [989] <.001yy
3 y [patients at risk] 69%  9% [836] 86%  8% [627] <.001yy
5 y [patients at risk] 60%  12% [508] 78%  11% [381] <.001yy
8 y [patients at risk] 40%  14% [246] 65%  14% [184] <.001yy
Freedom from cardiac events (%)
1 y [patients at risk] 80%  8% [1136] 100% [911] <.001yy
3 y [patients at risk] 70%  12% [815] 94%  2% [618] <.001yy
5 y [patients at risk] 61%  11% [476] 86%  6% [360] <.001yy
8 y [patients at risk] 53%  11% [228] 86%  6% [174] <.001yy
Freedom from rehospitalization (%)
1 y [patients at risk] 82%  7% [1295] 98%  1% [972] <.001yy
3 y [patients at risk] 73%  13% [820] 89%  8% [615] <.001yy
5 y [patients at risk] 61%  15% [492] 84%  8% [369] <.001yy
8 y [patients at risk] 36%  18% [230] 79%  14% [172] <.001yy
Postoperative complications were noted using the criteria of the Society of Thoracic Surgeons. *Significant bleeding was compromised hemodynamics, bleeding of at least 500
mL/h during the first postoperative hour, bleeding of at least 300 mL/h for 3 consecutive hours after chest closure, or bleeding of at least 1200 mL/h after the fifth postoperative
hour. yIdentified by the need for multiple inotropes or for an intra-aortic balloon pump in the postoperative period for at least 30 minutes. zDefined as elevation of cardiac enzymes
(50 IU) in association with new Q waves or ST-T interval. xAtrial fibrillation was noted when it was sustained for at least 30 minutes or required treatment. kDefined by clinical
criteria, including chest roentgenographic findings and sputum culture results that mandated antibiotic therapy. {Defined as a new, focal neurologic deficit lasting less than 24
hours. #Defined as a new, focal neurologic deficit that persisted at discharge. **Defined as death occurring within 30 days of operation. yySignificance by log-rank test.
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Dclinical history, clinical examination, and evaluation of
functional status remain the most important preoperative as-
sessment instruments. Patients who smoke cigarettes should
quit at least 8 weeks before surgery to minimize high airway1068 The Journal of Thoracic and Cardiovascular Surreactivity and the risk of bronchospastic obstruction of the
airway, mucus trapping, and regional atelectasis, and
high-risk elderly patients should be trained in forced cough
and lung expansion techniques before surgery if possible,gery c November 2011
TABLE 3. Multivariable predictors of death
Adjusted
hazard ratio*
Bias-corrected
95% confidence
interval
P
value
Perioperative myocardial
infarction
2.9 1.7–4.0 <.001
Postoperative stroke 2.7 1.9–3.9 <.001
Postoperative renal failure 2.1 1.3–3.5 <.001
Chronic obstructive
pulmonary disease
1.9 1.5–2.5 <.001
Preoperative congestive heart
failure
1.6 1.3–2.0 <.001
Multiple valve procedure 1.2 1.0–1.5 .004
Urgent or emergency
procedure
0.7 0.5–0.9 .01
Prolonged ventilation 0.6 0.3–0.8 .04
*Validated by bootstrapping technique (1000 iterations). The model was fitted to
compute the hazard ratio for death after adjustment for potential confounders (hyper-
tension, smoking, diabetes, obesity, hypercholesterolemia, chronic renal disease,
chronic obstructive pulmonary disease, cerebrovascular disease, New York Heart As-
sociation functional class, EuroSCORE, pulmonary hypertension, endocarditis, pre-
vious percutaneous transluminal angioplasty, emergency associated procedures,
isolated coronary artery bypass grafting, multiple valve procedures, aortic crossclamp
time, cardiopulmonary bypass time). Backward stepwise selection was used, with a P
value to remove of .2.
TABLE 4. Quality of life assessment
80 y
HC UC Baseline
SF-36
Physical Functioning 52 [28–75] 41 [22–84] 40 [22–57]
Role Physical 45 [20–70] 25 [13–44] 12 [0–35]
Bodily Pain 62 [41–84] 40 [22–57] 36 [19–48]
General Health 40 [22–59] 35 [20–58] 30 [15–45]
Vitality 44 [28–59] 38 [23–54] 36 [12–48]
Social Functioning 62 [38–89] 47 [32–64] 50 [37–77]
Role Emotional 66 [20–87] 46 [22–74] 41 [12–62]
Mental Health 52 [34–75] 41 [28–70] 36 [26–68]
Physical composite score 50 [28–72] 35 [19–60] 29 [14–46]
Mental composite score 56 [34–71] 43 [26–65] 40 [21–63]
SAQ (n ¼ 987)
Physical limitation — — 42 [33–50]
Anginal stability — — 32 [21–48]
Anginal frequency — — 42 [24–57]
Treatment satisfaction — — 52 [74–90]
Disease perception — — 29 [23–35]
STAI
X1 35 [18–45] 40 [25–57] 42 [30–50]
X2 39 [36–50] 36 [27–42] 38 [29–45]
SDS
Raw score 40 [22–43] 49 [30–64] 48 [32–55]
Average score 2.1 [1.0–3.0] 2.4 [1.1–3.7] 2.4 [1.1–4.0]
Index 0.5 [0.3–0.7] 0.6 [0.2–0.8] 0.6 [0.2–0.9]
Quality of life of octogenarians undergoing heart operation were compared with 340 unop
comparison with a younger population, quality of life of septuagenarians undergoing oper
sented as median and interquartile range. HC, Healthy control [group]; UC, unoperated co
tionnaire; STAI, Spielberger State-Trait Anxiety Inventory; X1, form for state anxiety; X2, fo
versus baseline. ySignificant difference versus elderly patient group. zSignificant differenc
elderly patient group versus healthy control group. kSignificant difference of septuagenar
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Dbecause there is some evidence that preoperative regular
chest physiotherapy significantly decreases the incidence
of pulmonary complications.22 Furthermore, the stay in
the ICU was longer for elderly patients who underwent
combined CABG and valve surgery or aortic surgery than
for patients who underwent other types of cardiac surgery
and for patients younger than 80 years.
In our experience, however, the most common event af-
fecting the ICU stay is atrial fibrillation. With advancing
age, fibrosis in the atria increases, a situation that leads to
reentrant excitation and atrial fibrillation.22 The manage-
ment of atrial fibrillation should be based on the severity
of the signs and symptoms. In most instances, however, ini-
tial treatment focuses on controlling the rapid ventricular
response. The choice of antiarrhythmic agent should be
based on the presence or absence of structural heart disease
and the tolerability, ease of administration, and side effects
of the agent.22
The main finding of our study was that the CER of car-
diac procedures in octogenarians was higher than that in
septuagenarians (2.83-fold), as well as in UC (1.97-fold)
and HC (2-fold) groups. In our experience, the CER was70–79 y
Postoperative HC Baseline Postoperative
46 [24–68] 75 [45–90] 47 [28–64] 76 [36–88]*,y
45 [25–55]*,z 75 [30–100] 31 [29–66] 75 [35–90]*,x
70 [39–97]*,z,x 75 [41–100] 32 [33–74] 72 [60–100]*
45 [23–64]*,z 55 [34–73] 48 [21–59] 74 [58–85]*,y,k
44 [21–67] 56 [40–75] 33 [19–59] 58 [35–72]*,x
73 [45–86]*,z,x 75 [50–100] 53 [34–79] 90 [75–100]*,y,k
75 [67–92]*,z,x 92 [43–100] 58 [20–56] 94 [67–100]*,y
42 [20–67]x 65 [45–82] 56 [33–72] 74 [60–80]*,y
51 [27–71]*,z 70 [20–91] 40 [28–65] 74 [48–93]*,y
58 [38–78]*,z 71 [44–90] 41 [26–66] 82 [60–94]*,y,k
77 [63–92]* — 44 [33–55] 83 [63–100]*,y
67 [55–80]* — 35 [24–51] 94 [83–100]*,y
79 [67–91]* — 39 [26–53] 92 [79–100]*,y
76 [76–96]* — 51 [73–89] 88 [77–100]*,y
76 [68–82]* — 34 [28–40] 93 [82–100]*,y
35 [28–43]* 25 [14–29] 39 [28–45] 25 [19–36]*,y
36 [27–42] 28 [13–34] 38 [28–45] 30 [20–42]*,y
58 [26–67]*,z,x 30 [21–44] 44 [28–64] 36 [20–40]*,y
2.9 [1.3–4.5]*,z,x 1.4 [0.8–1.6] 2.2 [1.2–3.5] 1.8 [0.9–2.0]*,y
0.7 [0.6–0.9]*,z,x 0.3 [0.1–0.5] 0.5 [0.3–0.6] 0.4 [0.3–0.5]*,y
erated control subjects and with 600 age-matched healthy control subjects. To allow
ation was compared with that of age-matched healthy control subjects. Data are pre-
ntrol [group]; SF-36, 36-Item Short-Form Health rating; SAQ, Seattle Angina Ques-
rm for trait anxiety; SDS, Zung Self-Rating Depression Scale. *Significant difference
e of elderly patient group versus unoperated control group. xSignificant difference of
ian patient group versus healthy control group.
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TABLE 5. Cost data by service area
80 y 70–79 y P value
Preoperative $914 [$390–$1470] $693 [$297–$1560] .4
Anesthesia $1603 [$968–$1944] $1199 [$950–$1586] .07
Operative $3783 [$1710–$4887] $3499 [$1680–$4570] .1
Perfusion $2674 [$1500–$3885] $2180 [$1260–$2650] .06
Intensive care unit $2853 [$1518–$3980] $1990 [$910–$2720] .006
Postoperative room $1103 [$281–$1230] $840 [$210–$ 996] .3
Respiratory therapy $1431 [$670–$1695] $575 [$58–$201] .006
Laboratory $493 [$140–$655] $328 [$110–$487] .8
Blood bank $804 [$310–$1930] $250 [$107–$340] .04
Cardiology laboratory $162 [$90–$231] $186 [$100–$210] .9
Radiology $196 [$55–$281] $101 [$47–$225] >.9
Pharmacy $2087 [$1077–$2599] $1185 [$420–$1313] <.001
Therapies $424 [$101–$560] $248 [$96–$512] .07
Supplies $318 [$48–$543] $290 [$35–$469] >.9
Other $197 [$38–$355] $185 [$30–$341] >.9
Total direct cost $19,042 [$10,975–$29,479] $13,749 [$6464–$18,856] <.001
Total direct costs of octogenarians and septuagenarians undergoing cardiac surgery were compared. Data are presented as median and interquartile range. Prices are in US dollars
but were originally calculated in euros (V1¼ $1.34829 US as ofMay 29, 2007). Preoperative includes all costs from admission to surgery.Anesthesia includes cost of anesthetics,
equipment, and disposables used by anesthesiologists. Operative includes costs of surgery, use of the operating room, surgical equipment, and disposables used by surgeons.
Perfusion includes cost of cardiopulmonary bypass equipment, cardioplegia, and disposables used by the perfusionists. Intensive care unit includes cost of nursing, equipment,
and room in the intensive care unit. Postoperative room includes cost of nursing, equipment, and room on the step-down unit. Respiratory therapy includes costs related to re-
spiratory equipment. Laboratory includes cost of blood tests. Blood bank includes cost of blood typing and transfusion. Cardiology laboratory includes cost of electrocardio-
grams, echocardiograms, and noninvasive vascular studies. Radiology includes cost of radiologic examinations, computed tomographic scans, and magnetic resonance scans.
Pharmacy includes cost of pharmacy drugs and service. Therapies includes cost of physical, occupational, and speech therapies.
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Dvery high ($94,426), and cardiac surgery proved not to be
cost effective for elderly patients undergoing aortic surgery
or associated CABG and valve procedures and barely cost-
effective for other cardiac surgery interventions. Our find-
ings are in contrast with those of Wu and coworkers,11,23,24
who carried out a very precise economic analysis on 4617
patients undergoing aortic valve replacement and
concluded that this procedure is very cost-effective, espe-
cially for elderly patients. Apart from differences with our
patient population, which included all cardiac surgical in-
terventions other than valve procedures, our dissimilar re-
sults might be due mainly to the different method used to
estimate life years in our UC group.
Is cardiac surgery in octogenarians always reasonable?
Cardiac surgeons, cardiologists, and general practitioners
should consider that results must justify the investment
and that quality of life, costs, and cost–benefit are valuable
surgical end points. When an elderly patient is brought to
our attention as ‘‘in good form, looking younger than his
or her age,’’ we should keep in mind the words of Thibault’sTABLE 6. Multivariable predictors of in-hospital costs
Variable Coefficient 95% C
Age 80 y 0.7641 0.6162–0.9
Intensive care unit stay 0.4012 0.2611–0.5
Hospital Stay 0.3153 0.6402–0.4
Prolonged intubation 0.2199 0.1309–0.3
Sternal infection 0.0539 0.0111–0.0
Intercept 9.1098 8.9077–9.3
Goodness of fit expressed by likelihood ratio c2 81.741, P<.001. CI, Confidence interva
1070 The Journal of Thoracic and Cardiovascular Surdiscussant, who said, ‘‘There is nothing like cardiac surgery
to bring out a patient’s true age.’’25 There is abundant evi-
dence that elderly patients properly selected and referred
to cardiac surgery have improvements in their health, qual-
ity of life, and life expectancy, and that under these circum-
stances the treatment is worth its costs and resources used.
On the other hand, although denying surgery to those
elderly patients who have no chance of benefiting from op-
eration might not be ethically incorrect, surgery ‘‘at any
cost’’ not supported by any scientific evidence might well
be morally wrong.
Certainly, decision making is often difficult, and weighing
the risk–benefit of surgery may be a complex matter, particu-
larly for elderly patients. Furthermore, currently available
risk assessments are certainly suboptimal in this setting.
A refinement of adopted patient selection criteria or factors
influencing postoperative outcome should be addressed.
Once these advances in patients selection and risk analysis
have been achieved, a more ethical and appropriate cost-
effectiveness estimateof surgical treatmentwould bepossibleI SE X2 P value
143 0.0650 11.84 <.001
413 0.0813 5.60 <.001
329 0.0711 4.75 <.001
218 0.0482 4.29 <.001
971 0.0231 2.44 .004
013 0.0990 92.36 <.001
l.
gery c November 2011
TABLE 7. Cost data by service area by surgical procedure
CABG OPCAB AVR MV replacement MV repair Ao surgery CABGþvalve
Preoperative
80 y $897 [$402–$1437] $856 [$388–$1412] $922 [$418–$1478] 958 [$438–$1514] 885 [$411–$1420] 901 [$412–$1487] 944 [$444–$1533]
70–79 y $669 [$307–$1286] $648 [$295–$1244] $731 [$311–$1392] 762 [$330–$1417] 680 [$299–$1274] 700 [$307–$1361] 738 [$322–$1337]
P value .41 .42 .09 .10 .42 .10 .25
Anesthesia
80 y $1580 [$902–$1640] $1495 [$880–$1590] $1600 [$960–$1980] 1680 [$1058–$2030] 1593 [$954–$1875] 1564 [$930–$1904] 1650 [$1004–$2044]
70–79 y $1185 [$938–$1374] $958 [$650–$1120] $1191 [$993–$1392] 1240 [$1070–$1480] 1174 [$980–$1420] 1191 [$100–$1386] 1234 [$1080–$1473]
P value .08 .05 .07 .07 .07 .08 .07
Operative
80 y $2489 [$1419–$3012] $2129 [$1150–$2885] $4848 [$2618–$5966] 4864 [$2688–$5837] 2516 [$1344–$3133] 5060 [$2740–$6720] 5206 [$2910–$6984]
70–79 y $2303 [$1207–$2874] $2003 [$1013–$2746] $4485 [$2312–$5231] 4500 [$2210–$5341] 2328 [$1225–$3798] 4681 [$2318–$3995] 4816 [$2444–$5795]
P value .73 .68 .51 .47 .44 .31 .09
Perfusion
80 y $2320 [$1235–$3088] — $2412 [$1380–$3220] 2935 [$1675–$3890] 2635 [$1525–$3870] 2920 [$1610–$3990] 2897 [$1590–$3901]
70–79 y $1970 [$1060–$2390] — $2015 [$1150–$2542] 2440 [$1405–$2800] 2110 [$1245–$2645] 2380 [$1320–$2704] 2440 [$1395–$2784]
P value .08 — .08 .06 .05 .05 .06
Intensive care unit
80 y $2620 [$1515–$3600] $2380 [$1375–$3573] $2640 [$1485–$3678] 2760 [$1555–$3730] 2600 [$1410–$3630] 3540 [$2190–$4207] 3410 [$2104–$4140]
70–79 y $1934 [$1225]–$2634 $1849 [$1056–$2412] $1914 [$1202–$2599] 1940 [$1250–$2638] 1874 [$1130–$2470] 2319 [$1660–$2850] 2114 [$1490–$2780]
P value .02 .05 .01 .099 .01 <.01 <.01
Postoperative room
80 y $940 [$330–$1102] $860 [$280–$1103] $978 [$384–$1170] 1310 [$806–$1202] 835 [$274–$1094] 1385 [$850–$9240] 1340 [$840–$1275]
70–79 y $804 [$225–$955] $550 [$105–$741] $800 [$220–$988] 1015 [$301–$1188] 602 [$207–$807] 1070 [$312–$1210] 988 [$242–$1077]
P value .8 .2 .7 .1 .4 .9 .9
Respiratory therapy
80 y $1211 [$570–$1490] $1180 [$510–$1416] $1423 [$650–$1670] 1650 [$770–$1890] 1132 [$502–$1400] 1745 [$800–$1950] 1687 [$795–$1912]
70–79 y $550 [$52–$200] $410 [$40–$164] $545 [$50–$195] 688 [$72–$204] 440 [$45–$178] 736 [$84–$251] 740 [$86–$263]
P value .006 .007 .008 .009 .006 .01 .02
Laboratory
80 y $451 [$112–$615] $355 [$804–$570] $460 [$120–$635] 560 [$154–$707] 380 [$117–$569] 585 [$171–$871] 610 [$194–$965]
70–79 y $245 [$98–$410] $234 [$81–$375] $240 [$90–$400] 412 [$210–$612] 238 [$86–$388] 454 [$240–$646] 486 [$271–$712]
P value .5 .9 .4 .8 .8 .9 .8
Blood bank
80 y $660 [$265–$1773] $594 [$221–$1685] $680 [$279–$1797] 894 [$334–$2010] 735 [$309–$1888] 1024 [$390–$2155] 975 [$355–$2087]
70–79 y $215 [$99–$302] $123 [$45–$189] $210 [$95–$297] 320 [$198–$512] 219 [$107–$311] 395 [$210–$474] 372 [$202–$437]
P value .07 .06 .06 .04 .05 .03 .03
Cardiology laboratory
80 y $90 [$45–$127] $85 [$38–$115] $160 [$88–$329] 174 [$97–$247] 105 [$71–$187] 237 [$115–$325] 260 [$129–$347]
70–79 y $115 [$60–$135] $112 [$57–$129] $185 [$100–$207] 190 [$107–$215] 139 [$85–$188] 265 [$184–$375] 280 [$192–$414]
P value >.9 >.9 >.9 >.9 >.9 >.9 >.9
Radiology
80 y $180 [$44–$259] $131 [$27–$212] $194 [$52–$277] 214 [$64–$295] 170 [$36–$244] 284 [$98–$335] 201 [$60–$286]
70–79 y $78 [$35–$177] $53 [$15–$89] $63 [$25–$102] 136 [$52–$256] 75 [$30–$171] 175 [$66–$272] 134 [$50–$249]
P value >.9 >.9 >.9 >.9 >.9 >.9 >.9
Pharmacy
80 y $2020 [$1007–$2486] $1950 [$977–$2379] $2034 [$1028–$2510] 2100 [$1090–$2610] 2012 [$988–$2415] 2090 [$1075–$2590] 2074 [$1057–$2533]
70–79 y $1206 [$434–$1330] $935 [$180–$1089] $1116 [$282–$1254] 1360 [$597–$1410] 1100 [$277–$1250] 1295 [$502–$1407] 1270 [$495–$1391]
P value .009 <.001 <.001 .01 <.001 .01 .009
Therapies
80 y $409 [$106–$524] $320 [$70–$455] $399 [$101–$519] 443 [$121–$585] 386 [$97–$493] 515 [$154–$698] 474 [$137–$622]
70–79 y $235 [$85–$491] $198 [$58–$431] $223 [$74–$437] 268 [$107–$525] 220 [$70–$469] 294 [$132–$561] 286 [$124–$547]
P value .7 .9 .7 .7 .7 .4 .6
Supplies
80 y $301 [$44–$501] $298 [$25–$473] $319 [$50–$550] 324 [$64–$559] 319 [$56–$559] 336 [$71–$584] 325 [$66–$573]
70–79 y $290 [$30–$461] $274 [$24–$444] $290 [$34–$467] 302 [$44–$489] 304 [$44–$489] 305 [$47–$493] 299 [$36–$473]
P value >.9 >.9 >.9 >.9 >.9 >.9 >.9
Other
80 y $190 [$30–$332] $145 [$15–$215] $200 [$41–$359] 218 [$56–$381] 195 [$34–$349] 224 [$63–$386] 212 [$54–$373]
70–79 y $178 [$27–$326] $122 [$20–$291] $188 [$34–$353] 206 [$50–$370] 179 [$30–$334] 219 [$61–$383] 203 [$46–$361]
P value >.9 >.9 >.9 >.9 >.9 >.9 >.9
Total costs
80 y $16,759
[$13,696–$28,612]
$13,178
[$10,494–$23,461]
$19,760
[$11,340–$30,100]
$21,307
[$12,430–$34,215]
$16,902
[$10,708–$28,635]
$22,814
[$12,504–$34,646]
$22,666
[$12,496–$34,620]
(Continued)
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TABLE 7. Continued
CABG OPCAB AVR MV replacement MV repair Ao surgery CABGþvalve
70–79 y $12,212
[$6120–$1822]
$8308
[$3220–$12,615]
$14,431
[$6512–$19,436]
$16,019
[$8440–$23,619]
$11,917
[$5665–$17,746]
$16,714
[$9762–$25,220]
$16,650
[$8979–$24,011]
P value <.001 <.001 <.001 <.001 <.001 <.001 <.001
Total direct costs of octogenarians and septuagenarians undergoing cardiac surgery were compared. Data are presented as median and interquartile range. Prices are in US dollars
but were originally calculated in euros (V1¼ $1.34829 US as ofMay 29, 2007). Preoperative includes all costs from admission to surgery.Anesthesia includes cost of anesthetics,
equipment, and disposables used by anesthesiologists. Operative includes costs of surgery, use of the operating room, surgical equipment, and disposables used by surgeons.
Perfusion includes cost of cardiopulmonary bypass equipment, cardioplegia, and disposables used by the perfusionists. Intensive care unit includes cost of nursing, equipment,
and room in the intensive care unit. Postoperative room includes cost of nursing, equipment, and room on the step-down unit. Respiratory therapy includes costs related to re-
spiratory equipment. Laboratory includes cost of blood tests. Blood bank includes cost of blood typing and transfusion. Cardiology laboratory includes cost of electrocardio-
grams, echocardiograms, and noninvasive vascular studies. Radiology includes cost of radiologic examinations, computed tomographic scans, and magnetic resonance scans.
Pharmacy includes cost of pharmacy drugs and service. Therapies includes cost of physical, occupational, and speech therapies.CABG,Coronary artery bypass grafting;OPCAB,
off-pump coronary artery bypass grafting; AVR, aortic valve replacement; MV, mitral valve; Ao, aortic.
FIGURE 1. A, Cost-effectiveness by surgical procedure in octogenarians
and septuagenarians undergoing cardiac surgery. Cost per quality-adjusted
life year (QoL) was significantly lower in septuagenarians independent of
the type of procedure. B, Cost-effectiveness ratio (CER) by surgical proce-
dure in octogenarians and septuagenarians undergoing cardiac surgery. The
CER for octogenarians was higher than $100,000 for aortic surgery and as-
sociated coronary artery bypass grafting and valve surgery; it was, how-
ever, above $20,000 in all cases. CABG, Coronary artery bypass grafting;
OPCAB, off-pump coronary artery bypass grafting; AVR, aortic valve re-
placement; MVR, mitral valve replacement; MV, mitral valve.
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cations so that patients can truly take advantage of surgery.
Undoubtedly, the increase in the cost of high-tech cardio-
vascular treatments and the parallel increase in the limitation
of economic resources will certainly force us to consider
econometric aspects in health care strategies. This will
make econometric analysis an important component for
any future evaluation of novel cardiovascular therapy.Limitations
The scores of questionnaires may overestimate in some
areas because of the possible bias of telephonic interview.
The life years of our UC and HC groups were also estimated
with a statistical model, although the Gompertz regression
has been widely used to model survival time in survival
analysis, especially for elderly persons. Lifetime costs of
HC and UC groups were obtained from the general Italian
population and applied to patients. For calculation of the
CER, the costs of maintaining a patient in the UC group
was set at 0, which could overestimate the CER. Thus the
maximum value from this formula would be $94,000; in re-
ality, however, it could be substantially less than that. Fi-
nally, the CER was estimated by mapping quality of life
score to NYHA functional class, which is not a perfect mea-
sure of quality of life, although it has been demonstrated to
correlate with quality of life.
A strength of our study was the direct measurement of
costs for UC and HC groups from direct measurement of re-
sources during a prolonged period of clinical observation.
The different categorizations of costs between the opera-
tive, HC, andUCgroupsmight have affected the overall cost
analysis. For example, home care facilities for the postoper-
ative costs were not equivalent to home and skilled nursing
facilities costs for HC and UC groups. In addition, only pa-
tients with preoperative diagnosis of severe depression were
treated. Indeed, mild or subclinical depression was not as-
sessed and treated, thus potentially representing a negative
determinant of postoperative recovery, and this should be
taken into consideration when interpreting our findings.
Furthermore, there was no uniformity regarding the inter-
val after surgery at which the tests were administered, and itgery c November 2011
APPENDIX TABLE 1. Terminology specific to quality of life
measurement
Term Meaning
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standable pattern of change with time in the postoperative
SF-36 score, and that results for a given individual will
vary depending on how long postoperatively the test is ad-
ministered. Additionally, all procedures were performed in
different centers. We did, however, account for hypothetic
difference in surgical conduct among Institutions participat-
ing in the study, and no significant difference was found.
Finally, it is of interest that the additive and logistic Euro-
SCORE values were lower (although not significantly) in
the octogenarian group than in the septuagenarian group.
This suggests that an inherent selection bias, which does ex-
ist in evaluating octogenarians for intervention, contributed
to the clinical component of this analysis.
CONCLUSIONS
In our experience, cardiac surgery in octogenarians was
shown not to be always cost-effective. Advances in cost as-
sessment and more comprehensive patients evaluation (eg,
frailty score in addition to currently available risk scores)
would be essential to generate appropriate patient manage-
ment. It is to be hoped that such advances would lead to
more ethical and more appropriately economically oriented
decision making for surgical candidates.
This study was not intended to demonstrate that surgery
should generally be questioned for these patients only on
the basis of service use and economic implications. It was
and is intended as a call for a comprehensive evaluation
of such a highly controversial issue, which because of
increasing economic constraints and new therapeutic
advances will be even more controversial in the future.
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Dr Orlando Parise for the statistical analysis.SF-36 Medical Outcomes Short Form 36 Item Health Survey
PF Physical Functioning
RP Role Physical
BP Bodily Pain
GH General Health
VT Vitality
SF Social Functioning
RE Role Emotional
MH Mental Health
PCS Physical composite score (PFþRPþBPþGH)
MCS Mental composite score (MHþREþVTþSF)
SAQ The Seattle Angina Questionnaire
STAI Spielberger State-Trait Anxiety Inventory
X1 STAI to measure state anxiety (how one feels
at a particular moment
X2 STAI to measure trait anxiety (how one usually feels)
SDS Self-Rating Depression Scale of ZungReferences
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